Correlation between Serum IL-35 Levels and Bone Loss in Postmenopausal Women with Rheumatoid Arthritis

Table 1

Clinical parameters of RA and HCs.

Characteristics	RA ()	HCs ()	value
Demographics
Age, years,	52.5 (2.4)	53.3 (2.8)	0.56
Menopause, years,	48.5 (2.1)	49.0 (2.0)	0.39
Duration of postmenopausal period, years,	8.9 (2.4)	8.2 (2.2)	0.41
Disease duration, months, median (IQR)	4.8 (0.7-7.0)	—
Disease characteristics
ESR, mm/h,	68.4 (2.7)	—
CRP, mg/L,	44.0 (3.9)	—
TJC,	9 (1.2)	—
SJC,	6 (1.1)	—
RF (+), (%)	42 (55.3)	—
ACPA (+), (%)	53 (69.7)	—
DAS28-ESR	6.6 (1.2)	—
Medications
HCQ, (%)	36 (47.4)	—
MTX, (%)	18 (23.7)	—
LEF, (%)	16 (21.1)	—
TG, (%)	16 (21.1)	—
DXA
Normal, (%)	17 (22.4)	17 (32.1)	<0.01
Osteopenia, (%)	44 (57.9)	27 (50.9)	0.04
Osteoporosis, (%)	15 (19.7)	9 (17.0)	0.04
Lumbar spine (L1-L4)
BMD, g/cm^2,	0.8 (0.3)	1.0 (0.3)	0.03
T score,	-2.2 (0.4)	-0.9 (0.4)	0.07
Z score,	-1.1 (0.4)	-0.5 (0.4)	0.06
Total hip
BMD, g/cm^2,	0.8 (0.3)	1.0 (0.4)	0.04
score,	-1.3 (0.4)	-0.9 (0.4)	0.07
score,	-1.2 (0.3)	-0.6 (0.3)	0.06
BTMs
Serum β-CTX, pg/mL, median (IQR)	340.3 (181.1-394.1)	123.6 (111.2-218.2)	<0.0001
Serum ALP, U/L, median (IQR)	78.0 (66.2-96.5)	60.1 (42.0-81.5)	0.1
Serum 25-(OH) VitD3, ng/mL median (IQR)	10.1 (6.4-14.8)	41.8 (8.1-13.3)	<0.0001

Abbreviations: ESR: erythrocyte sedimentation rate; CRP: C-reaction protein; TJC: tender joint count; SJC: swollen joint count; DAS28-ESR: disease activity score in 28 joints with sedimentation; RF: rheumatoid factor; ACPA: anticyclic citrullinated peptide antibodies; β-CTX: C-terminal cross-linked telopeptides of type I collagen; BMD: bone mineral density; HCQ: hydroxychloroquine; MTX: methotrexate; LEF: leflunomide; TG: tripterygium glycosides.